EICHORPublic-registry site landscape for NCT05673811, “Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer”, a Pancreatic Adenocarcinoma study sponsored by Theriva Biologics SL. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05673811 (registry record) |
| Study title | Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer |
| Official title | A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer |
| Sponsor | Theriva Biologics SL |
| Condition(s) | Pancreatic Adenocarcinoma; Metastatic |
| Phase | PHASE2 |
| Listed sites | 17 |
| Intervention(s) | Nab-paclitaxel, Gemcitabine |
| Site countries | United States, Spain |
Patient-friendly overview of this study: eichor.com/study/NCT05673811.
Eichor generates a preliminary site-risk snapshot for NCT05673811 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Pancreatic Adenocarcinoma trials
← Eichor home · All tracked trials · Pancreatic Adenocarcinoma studies · Weekly briefs
